Skip to main content

Table 1 Assay parameters of imaging modalities and classical biomarkers used in detection of pancreatic cancer

From: Advance in microRNA as a potential biomarker for early detection of pancreatic cancer

Item AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) Reference
CT 0.832 92 - 80 67 - [19]
MRI 0.92 100 - 90 100 - [19]
EUS-FNA - 82.1 100 100 79.2 89.4 [20]
MRCP - - - 85 - 80 [21]
ERCP - - - 88 - 85 [21]
MRI+ERCP - - - 91 - 88 [21]
18F-FDGPE/CT 0.759 67.50 72.73 94.74 23.53 68.13 [22]
CA19-9 0.857 75.00 81.82 96.77 31.03 75.82 [22]
18F-FDGPE/CT + CA19-9 0.940 96.25 63.64 95.06 70.00 92.31 [22]
CA125 0.810 78.68 71.05 79.63 51.92 - [23]
CEA 0.670 63.24 63.16 75.44 48.98 -
CA50 0.630 52.21 78.95 81.61 48.00 -
CA724 0.670 65.44 68.42 78.76 52.53 -
CA242 0.640 64.71 60.53 74.58 48.94 -
AFP 0.490 43.38 61.84 67.05 37.90 -
  1. The assay parameters are for diagnosis of differentiation between adenocarcinoma and nonadenocarcinoma. Small liver metastases (0.5 – 1 cm in diameter) were missed on CT and MRI. Adequate specimens were obtained by EUS-FNAB from 47 of the 50 pancreatic lesions (94.0 %). CA125, CEA, CA50, CA50, CA724, CA242 and AFP are for patients with unresectable pancreatic cancer misjudged as resectable tumor by CT scan. AUC area under the curve, NPV negative predictive value, PPV positive predictive value, − No data was available in these instances